| Budget Amount *help |
¥4,940,000 (Direct Cost: ¥3,800,000、Indirect Cost: ¥1,140,000)
Fiscal Year 2013: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Fiscal Year 2012: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2011: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
|
|---|
| Research Abstract |
Monoclonal antibodies are widely used for patients with gastric or colorectal cancer. These drugs have direct effect on the tumor cells, however modulation of the immune response could be another important mechanism. Antibody dependent cellular cytotoxicity (ADCC) mediated through the receptor (FcR) of the antibodies carried by immune cells plays an important role in the antitumor effect of the antibody. In this study, we confirmed that both monoclonal antibodies of trastuzumab and cetuximab had ADCC activity, however immunomodulator lentinan showed no augmentation of ADCC. Genetic features of FcR polymorphisms may be associated with the outcome of cancer patients treated with monoclonal antibodies.
|
